Adverum Biotechnologies, Inc. financial data

Symbol
ADVM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Cardinal Way, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Avalanche Biotechnologies, Inc. (to 5/10/2016)
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 665 % +60.3%
Debt-to-equity 60.8 % -22.4%
Return On Equity -65.1 % +26%
Return On Assets -40.5 % +17.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.8M shares -79.4%
Common Stock, Shares, Outstanding 101M shares +1.31%
Entity Public Float 152M USD +32.1%
Common Stock, Value, Issued 2K USD -80%
Weighted Average Number of Shares Outstanding, Basic 20.9M shares +107%
Weighted Average Number of Shares Outstanding, Diluted 20.9M shares +107%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD -72.2%
Research and Development Expense 68.2M USD -19.4%
General and Administrative Expense 35.9M USD -29.3%
Operating Income (Loss) -103M USD +21.8%
Nonoperating Income (Expense) 7.86M USD +38.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -95.2M USD +24.5%
Income Tax Expense (Benefit) -1.13M USD -1631%
Net Income (Loss) Attributable to Parent -94.1M USD +25.4%
Earnings Per Share, Basic 4.44 USD/shares +60.1%
Earnings Per Share, Diluted 4.44 USD/shares +60.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 92.9M USD -11.9%
Cash, Cash Equivalents, and Short-term Investments 153M USD +30.8%
Assets, Current 161M USD +29.3%
Property, Plant and Equipment, Net 12.2M USD -21.2%
Operating Lease, Right-of-Use Asset 50.7M USD -3.91%
Other Assets, Noncurrent 1.29M USD +1.81%
Assets 234M USD +19.1%
Accounts Payable, Current 2.11M USD -2.77%
Liabilities, Current 27.7M USD -4.16%
Operating Lease, Liability, Noncurrent 62.6M USD -3.99%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 90.3M USD -4.04%
Accumulated Other Comprehensive Income (Loss), Net of Tax -268K USD +51.4%
Retained Earnings (Accumulated Deficit) -990M USD -10.5%
Stockholders' Equity Attributable to Parent 144M USD +40.3%
Liabilities and Equity 234M USD +19.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.2M USD -3.72%
Net Cash Provided by (Used in) Financing Activities 120M USD
Net Cash Provided by (Used in) Investing Activities -22M USD -202%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 101M shares +1.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 74.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 94.8M USD -12.2%
Deferred Tax Assets, Valuation Allowance 205M USD +9.02%
Deferred Tax Assets, Gross 219M USD +5.41%
Operating Lease, Liability 75M USD -17.5%
Payments to Acquire Property, Plant, and Equipment 90K USD +5.88%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.8M USD +24.8%
Lessee, Operating Lease, Liability, to be Paid 141M USD -14.8%
Property, Plant and Equipment, Gross 29.5M USD +1.56%
Operating Lease, Liability, Current 10.7M USD +3.26%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.4M USD -3.45%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.1M USD -3.47%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 66.2M USD -11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.8M USD -3.44%
Deferred Tax Assets, Operating Loss Carryforwards 128M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 24.6M USD -0.53%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.2M USD -3.42%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 13.6M USD -29.6%
Share-based Payment Arrangement, Expense 15.2M USD -18.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%